Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
Abroad (travel likely)Recruiting
Conditions
Extensive-stage Small-cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Henan Cancer Hosipital, Zhengzhou, Henan, China
Study leads
Chen Li Juan, Prof
Principal Investigator
Henan Cancer Hospital